Durable Responses With Brentuximab Vedotin in cHL

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2016-100
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2014English

Oral Mycosis Fungoides With CD30+ Large Cell Transformation Successfully Treated With Brentuximab Vedotin

JAAD Case Reports
Dermatology
2019English

Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Bőrgyógyászati és Venerológiai Szemle
2019English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

A Case of Refractory Sézary Syndrome With Large-Cell Transformation Responsive to Brentuximab Vedotin

JAMA Dermatology
DermatologyMedicine
2014English

Brentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Review

Critical Reviews in Oncology/Hematology
GerontologyGeriatricsHematologyOncology
2017English

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Pcn175 - Brentuximab Vedotin Compared With Standard Therapy for Patients With Advanced-Stage Hodgkin’s Lymphoma: A Cost-Effectiveness Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy